Cargando…

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

Background: The inactivation of tumor-suppressor p53 plays an important role in second generation anti-androgens (SGAs) drug resistance and neuroendocrine differentiation in castration-resistant prostate cancer (CRPC). The reactivation of p53 by blocking the MDM2–p53 interaction represents an attrac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Meng, Cui, Jingyi, Hou, Huimin, Li, Ying, Liu, Shengjie, Wan, Li, Zhang, Lili, Huang, Wei, Sun, Gaoyuan, Liu, Jingchao, Jin, Pengfei, He, Shunmin, Liu, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081362/ https://www.ncbi.nlm.nih.gov/pubmed/35548335 http://dx.doi.org/10.3389/fphar.2022.871259

Ejemplares similares

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke(®) and Glucophage(®)-XR) in healthy Chinese volunteers: a randomized phase I clinical trial
por: Sun, Ming-Li, et al.
Publicado: (2022)

Ultraviolet exposure of Gafchromic XR‐RV3 and XR‐SP2 films
por: Katsuda, Toshizo, et al.
Publicado: (2015)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer
por: Huang, Jia-Luo, et al.
Publicado: (2023)

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities
por: Sawaguchi, Yuichi, et al.
Publicado: (2021)

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2018)

An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling In Vitro
por: Su, Tao, et al.
Publicado: (2017)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
por: Fang, Douglas D., et al.
Publicado: (2021)

Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET(®) XR in healthy volunteers under fasting and fed conditions
por: Que, Linling, et al.
Publicado: (2023)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

Dosimetric evaluation of GAFCHROMIC® XR type T and XR type R films
por: Dini, Sharifeh A., et al.
Publicado: (2005)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction
por: Shiheido, Hirokazu, et al.
Publicado: (2011)

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
por: Qin, Jiang-Jiang, et al.
Publicado: (2017)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
por: Hirabatake, Masaki, et al.
Publicado: (2022)

In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
por: Mistry, P, et al.
Publicado: (1999)

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia
por: Trino, Stefania, et al.
Publicado: (2016)

Ligand-Based and Docking-Based Virtual Screening of MDM2 Inhibitors as Potent Anticancer Agents
por: Li, Bing-Hui, et al.
Publicado: (2021)

A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance
por: Wang, Wei, et al.
Publicado: (2019)

Cisco IOS XR fundamentals
por: Tahir, Mobeen
Publicado: (2009)

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
por: Tang, Lin, et al.
Publicado: (2021)

HIV-1 Tat potently stabilises Mdm2 and enhances viral replication
por: Raja, Rameez, et al.
Publicado: (2017)

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
por: Ananthapadmanabhan, Varsha, et al.
Publicado: (2022)

Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug—Design and Mechanism of Action
por: Buric, Adam J., et al.
Publicado: (2021)

Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma
por: Li, Ye, et al.
Publicado: (2021)

Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor
por: Zhang, Lihui, et al.
Publicado: (2019)

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer
por: Liu, Jinghui, et al.
Publicado: (2023)

Lipidomics reveals the potential mechanism of honokiol against adenine-induced chronic kidney disease
por: Liu, Xinhui, et al.
Publicado: (2022)

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
por: Lam, Wing, et al.
Publicado: (2023)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021)

How Do Structurally Distinct Compounds Exert Functionally Identical Effects in Combating Obesity?
por: Deng, Zhi-Jun, et al.
Publicado: (2018)

Ilicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway
por: Guo, Lang, et al.
Publicado: (2021)

Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia
por: Pan, Yunbao, et al.
Publicado: (2017)

Luteolin Exerts Neuroprotection via Modulation of the p62/Keap1/Nrf2 Pathway in Intracerebral Hemorrhage
por: Tan, Xin, et al.
Publicado: (2020)

Correlations between TBL1XR1 and recurrence of colorectal cancer
por: Liu, Hongda, et al.
Publicado: (2017)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
por: Wang, Bo-Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1l6410koukckuh87o2c6r3sli1